CLINICAL TRIALS PROFILE FOR CHOLINE FENOFIBRATE
✉ Email this page to a colleague
All Clinical Trials for choline fenofibrate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00616772 ↗ | Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood | Completed | AbbVie (prior sponsor, Abbott) | Phase 3 | 2008-02-01 | The primary purpose of this study is to test the effect and safety of once daily ABT-335 on the thickness of the lining of the carotid artery (a blood vessel to the brain) in patients with abnormal blood lipids who have optimal levels of low density lipoprotein cholesterol ("bad cholesterol") after taking atorvastatin. |
| NCT00639158 ↗ | Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood | Completed | Abbott | Phase 3 | 2008-02-01 | The primary purpose of this study is to compare the safety and efficacy of ABT-335 (investigational drug) coadministered with atorvastatin and ezetimibe to atorvastatin coadministered with ezetimibe in subjects with abnormal lipid (fat) levels in the blood. |
| NCT00673881 ↗ | ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study | Completed | Radiant Research | Phase 1/Phase 2 | 2008-03-01 | The objectives of the study are: 1. To evaluate the effect of ABT-335 (choline fenofibrate) on several parameters of RCT (reverse cholesterol transport) in men and post-menopausal women diagnosed with dyslipidemia (i.e., low high-density lipoprotein [HDL] cholesterol levels and elevated triglyceride [TG] concentrations). 2. To evaluate longitudinal changes in several parameters of RCT in subjects with low HDL. 3. To obtain pilot data for power calculations for subsequent comparative study. |
| NCT00683176 ↗ | Effect of Choline Fenofibrate (SLV348) on Macular Edema | Completed | Abbott Products | Phase 2 | 2008-09-01 | The purpose of this study is to evaluate the effect of choline fenofibrate on the regression of macular edema in eyes of subjects with type 2 diabetes mellitus (T2DM) presenting with diabetic macular edema (DME) |
| NCT01025492 ↗ | Study of Trilipix Effects on Lipids and Arteries | Terminated | Abbott | Phase 4 | 2009-11-01 | Fibrates reduce atherosclerosis and cardiovascular disease events. A major mechanism of this benefit appears to be their ability to raise plasma high density lipoprotein cholesterol (HDL-C), especially in patients with high triglyceride levels. This study will investigate the effects of the addition of Trilipix (fenofibric acid) versus placebo to ongoing statin treatment on high density lipoprotein (HDL) composition and arterial function in subjects with insulin resistance. |
| NCT01025492 ↗ | Study of Trilipix Effects on Lipids and Arteries | Terminated | University of Utah | Phase 4 | 2009-11-01 | Fibrates reduce atherosclerosis and cardiovascular disease events. A major mechanism of this benefit appears to be their ability to raise plasma high density lipoprotein cholesterol (HDL-C), especially in patients with high triglyceride levels. This study will investigate the effects of the addition of Trilipix (fenofibric acid) versus placebo to ongoing statin treatment on high density lipoprotein (HDL) composition and arterial function in subjects with insulin resistance. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for choline fenofibrate
Condition Name
Clinical Trial Locations for choline fenofibrate
Trials by Country
Clinical Trial Progress for choline fenofibrate
Clinical Trial Phase
Clinical Trial Sponsors for choline fenofibrate
Sponsor Name
